Daniel Welch - Seagen Independent Director
| SGENDelisted Stock | USD 228.74 0.19 0.08% |
Director
Mr. Daniel G. Welch is Independent Director of Seattle Genetics, Inc., since June 2007. From January 2015 to February 2018, Mr. Welch served as an Executive Partner of Sofinnova Ventures, a VC firm. Mr. Welch served as Chief Executive Officer and President of InterMune, Inc., a formerly publiclytraded biotechnology company, from September 2003 until InterMunes acquisition by Roche Holdings in September 2014, and, from May 2007 to October 2014, he served in the additional role of Chairman of the Board of InterMune. Before joining InterMune, he was Chairman and Chief Executive Officer of Triangle Pharmaceuticals from 2002 to 2003, which was acquired by Gilead in 2003. Prior to that, he was President of Biopharmaceuticals at Elan Corporation from 2000 to 2002. During his tenure at Elan he was responsible for its U.S. commercial operations, international subsidiaries, RD and diagnostics businesses. From 1987 to 2000, Mr. Welch served in various senior management roles at SanofiSynthelabo, now SanofiAventis, including Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business since 2007.
| Age | 60 |
| Tenure | 17 years |
| Professional Marks | MBA |
| Phone | 425 527 4000 |
| Web | https://www.seagen.com |
Daniel Welch Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Welch against Seagen stock is an integral part of due diligence when investing in Seagen. Daniel Welch insider activity provides valuable insight into whether Seagen is net buyers or sellers over its current business cycle. Note, Seagen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Seagen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Welch over six months ago Exercise or conversion by Daniel Welch of 1812 shares of Seagen subject to Rule 16b-3 | ||
Daniel Welch over six months ago Acquisition by Daniel Welch of 2044 shares of Seagen subject to Rule 16b-3 | ||
Daniel Welch over six months ago Exercise or conversion by Daniel Welch of 5150 shares of Seagen subject to Rule 16b-3 | ||
Daniel Welch over a year ago Exercise or conversion by Daniel Welch of 995 shares of Seagen subject to Rule 16b-3 |
Seagen Management Efficiency
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shehnaaz Suliman | Ultragenyx | 46 | |
| Andrew Saik | PDS Biotechnology Corp | 48 | |
| Donald Kufe | Madrigal Pharmaceuticals | 69 | |
| Raymond Kurzweil | United Therapeutics | 70 | |
| Bruce Kovner | Madrigal Pharmaceuticals | 69 | |
| Katherine Klein | United Therapeutics | 61 | |
| William Kennedy | TG Therapeutics | 73 | |
| Deborah Dunsire | Ultragenyx | 56 | |
| Richard Sykes | PDS Biotechnology Corp | 76 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| Sinclair Dunlop | Apellis Pharmaceuticals | 46 | |
| Rafale Tordjman | Ascendis Pharma AS | 44 | |
| James Daly | Halozyme Therapeutics | 56 | |
| Amy Schulman | Alnylam Pharmaceuticals | 57 | |
| George Scangos | Exelixis | 69 | |
| Richard Meier | Biomarin Pharmaceutical | 57 | |
| Kevin Starr | Alnylam Pharmaceuticals | 53 | |
| David McGirr | X4 Pharmaceuticals | 63 | |
| Stephen Glover | PDS Biotechnology Corp | N/A | |
| Julie Smith | Exelixis | 47 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 |
Seagen Inc Leadership Team
Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Dansey, Chief Medical Officer | ||
| Vaughn Himes, Executive VP of Process Sciences and Technical Operations | ||
| Daniel Welch, Independent Director | ||
| Felix Baker, Lead Independent Director | ||
| Nancy Simonian, Independent Director | ||
| Peggy Pinkston, IR Contact Officer | ||
| Charles Romp, Ex US | ||
| MS JD, Chief Officer | ||
| Darren Cline, Executive Vice President - Commercial | ||
| Eric Dobmeier, COO, Corporate Secretary | ||
| Todd Simpson, CFO and Principal Accounting Officer | ||
| Pinkston Peggy, Senior Director - Corporate Communications | ||
| David Gryska, Independent Director | ||
| David Caouette, VP Communications | ||
| Srinivas Akkaraju, Independent Director | ||
| Alpna Seth, Director | ||
| Matt Skelton, VP Marketing | ||
| Marc Lippman, Independent Director | ||
| Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development | ||
| Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary | ||
| Robert Lechleider, Senior Vice President - Clinical Development | ||
| Christopher Pawlowicz, Ex HR | ||
| Clay Siegall, Co-Founder, Chairman, CEO and Pres | ||
| Robin Taylor, Chief Commercial Officer | ||
| Dennis Benjamin, Senior Vice President - Translational Research | ||
| Roger MD, Pres RD | ||
| John Orwin, Director | ||
| John McLaughlin, Independent Director |
Seagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.35) % | |||
| Current Valuation | 42.06 B | |||
| Shares Outstanding | 188.66 M | |||
| Shares Owned By Insiders | 0.81 % | |||
| Shares Owned By Institutions | 88.82 % | |||
| Number Of Shares Shorted | 9.58 M | |||
| Price To Earning | 32.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Seagen Stock
If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |